Travere Therapeutics (TVTX) Net Margin (2014 - 2026)

Travere Therapeutics' (TVTX) quarterly Net Margin came in at 0.39% in Q1 2026, up 94.41% on a QoQ basis from 7.03% in Q4 2025.

Travere Therapeutics (TVTX) Net Margin (2014 - 2026) Analysis & Trends

Travere Therapeutics (TVTX) has 13 years of Net Margin data on file, last reported at 0.39% in Q1 2026.

Quarterly Net Margin changed N/A year-over-year to 0.39% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 34.55% (down 3424.0% YoY) and the FY2025 annual result came in at 265.75%, up 26615.0% from the prior year.
Net Margin grew to 0.39% in Q1 2026, from 7.03% in the prior quarter.
In the past five years, Net Margin ranged from a high of 646.92% in Q3 2023 to a low of 7.03% in Q4 2025.
A 5-year average of 64.78% and a median of 12.32% in 2022 frame the typical range for Net Margin.
Annual changes were most pronounced in 2023 — Net Margin soared 59561 bps — and 2024, when it sank 64702 bps.
Tracing TVTX's Net Margin over 5 years: stood at 67.53% in 2022, then plunged by 105 bps to 3.5% in 2023, then surged by 99 bps to 0.02% in 2024, then tumbled by 34933 bps to 7.03% in 2025, then soared by 94 bps to 0.39% in 2026.
The last three Net Margin figures came in at 0.39% (Q1 2026), 7.03% (Q4 2025), and 0.02% (Q4 2024), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Margin (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	32.99%
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	30.23%
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	30.33%
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	13.90%
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	30.98%
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	12.09%
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	12.74%
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-3.12%
10	Travere Therapeutics	5.85 Bn	5.85 Bn	162.52 Mn	-

Download Data